Why the study?
Does changing therapy for heart failure based on serial measures of NT-proBNP improve outcomes compared to independent clinical judgment?
Does changing therapy for heart failure based on serial measures of NT-proBNP improve outcomes compared to independent clinical judgment?
Answers are grounded in this paper and cite their sources.
Serial measures of NT-proBNP may be more effective than independent clinical judgment for guiding heart failure therapy.
The correlation of new biomarkers with In patients with coronary artery disease (CAD), left ventricular ejection fraction.Globally, coronary artery disease is a significant non-communicable disease issue. Numerous significant risk factors, including smoking, diabetes mellitus, dyslipidemia, and hypertension, can result in coronary artery disease. [1]. patient heart failure management. When following up on heart failure cohorts over an extended period of time, plasma BNP or NT-proBNP is a highly effective independent predictor of death and morbidity. Furthermore, it seems to be a reliable indicator of a positive reaction when beta blocker is added to anti-heart failure medication. When changing therapy for heart failure based on serial measures of NT-proBNP, as opposed to altering therapy based on independent clinical judgment, better results are expected.
No takes yet. Share an insight, caveat, or question.
Alhussainy et al. (2026) studied Coronary artery disease and heart failure. Biomarkers (GADF15, BNP, NT-proBNP) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: